Pearce IP is proud to announce that Founding Principal and Executive Lawyer, Patent & Trade Mark Attorney, Naomi Pearce, has been shortlisted as a finalist in the Lawyers Weekly Women in Law Awards in the category...
27 Sep 21 | CA | Apobiologix announced that Health Canada has approved Bambevi® (biosimilar bevacizumab) in combination with chemotherapy to treat specific types of colorectal, lung, brain and ovarian cancer. 02 Oct 21...
October 11 is UN International Day of the Girl Child, a day where we together recognise the unique challenges girls face around the world and seek to advance the rights of girls and women. In honour of this day, Pearce...
Recently, Merck Sharp & Dohme (MSD) (known as Merck & Co., Inc. in the US and Canada) announced a settlement and licence agreement with Pfizer Inc. in relation to MSD’s pneumococcal conjugate vaccine (PCV)...
27 Sep 21 | Hikma Pharmaceuticals announced that it will acquire Custopharm for an initial cash consideration of USD $375 million with a further USD $50 million in contingent consideration payable upon the achievement...
18 Sep 21 | Merck announced that the first results from Ph III trials of Keytruda® (pembrolizumab) showed a statistically significant and clinically meaningful improvement in recurrence-free survival compared to...
The Full Federal Court has held a supplier of cosmetic products (Self Care) liable to Allergan for infringing its BOTOX trade mark and for misleading or deceptive conduct. In doing so, the Court reached novel...
New .au domain names will be available in Australia from 24 March 2022. From this date, individuals, businesses and organisations with an Australian presence will be able to register a name of their choosing directly...
Originally published in the IAM Saturday Opinion on 11 September 2021. Australia was recently thrust into the global IP limelight when the Federal Court controversially determined that an artificial intelligence (AI)...
13 Sep 21 | Samsung Bioepis reported on a five-year follow-up study comparing ONTRUZANT® (trastuzumab biosimilar) with reference trastuzumab in early or locally advanced HER2 positive breast cancer. Samsung Bioepis...
02 Sep 21 | US | Amgen and Hospira appear ready to settle the ongoing dispute relating to Neupogen® (filgrastim). The matter was due to go to a jury trial on 20 September 2021. 06 Sep 21 | IN | Hetero announced that it...
A recent decision of Justice Burley in the Federal Court of Australia confirms that the bar for sufficiency and support has actually been raised by Australia’s 2012 ‘Raising the Bar’ law reforms. This is the second...
Pearce IP is proud to announce that Special Counsel, Patent Attorney and Trade Mark Attorney, Jennifer Enmon PhD, JD has been recognised by Lawyer Monthly (Women in Law Awards 2021) as Patents Lawyer of the Year for...
Pearce IP is proud to announce that Pearce IP’s Founding Principal and Executive Lawyer, Patent and Trade Mark Attorney, Naomi Pearce, has once again been recognised as a World Leading Patent Strategist by IAM Strategy...
26 Aug 21 | US | Two former executives of JHL Biotech plead guilty to conspiracy to steal trade secrets and commit wire fraud exceeding $101 million in the US District Court for the Northern District of California. The...
Australia was recently thrust into the global IP limelight when the Federal Court controversially determined that an artificial intelligence (AI) system, DABUS, can be an inventor of a patent. Reaction to this...
24 Aug 21 | UCB announced that it has gained EU marketing approval for Bimzelx® (bimekizumab), an IL-17A and IL-17F inhibitor indicated for the treatment of adults with moderate to severe plaque psoriasis. 25 Aug 21 |...
17 Aug 21 | US | The USPTO Patent Trial and Appeal Board (PTAB) will review Amgen’s US 8,273,707 Patent (related to NEULASTA® (pegfilgrastim) in an IPR challenge brought by Pfizer and Hospira. The PTAB declined to...
The Australian Federal Court has confirmed in Merck Sharp & Dohme Corp. v Sandoz Pty Ltd [2021] FCA 947 that, when a patent covers two pharmaceutical substances of the patentee, a patent term extension (PTE)...
Boutique specialist firm Pearce IP is delighted to announce that Senior Associate, Belinda Hartmann PhD commenced with Pearce IP last week. Belinda is a Trans-Tasman patent attorney with biological sciences expertise,...
05 Aug 21 | A new study reported that the safety profiles and pharmacokinetic parameters of Amgen’s ABP980 (biosimilar trastuzumab) and pertuzumab administered as an admixture in a single infusion bag is consistent...
29 Jul 21 | US | The American Academy of Ophthalmology pushed back against insurance company pressure to use new bevacizumab biosimilars off-label in eye treatment as alternatives to Avastin® (bevacizumab) in the...
27 Jul 21 | Abenza and BioXpress Therapeutics announced they have formed a new partnership to support biosimilar development and manufacturing. 28 Jul 21 | Prestige BioPharma announced that HD201 (proposed trastuzumab...
The Australian Federal Court in Thaler v Commissioner of Patents [2021] FCA 879 (30 July 2021) has determined that an artificial intelligence (AI) system, DABUS, can be an inventor of a patent. However, the Court also...
Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.
